The Gateway for Cancer Research Traditional Grant Program supports investigator-initiated Phase I and Phase II cancer clinical trials designed to deliver innovative treatments directly to patients and potentially change standards of care.
The program is open to investigators from institutions around the world and supports projects across all cancer types. Awards typically range from $200,000 to $1.5 million over two to five years. Gateway accepts applications throughout the year and reviews them in scheduled cycles. The next LOI deadline listed in the application portal is November 6, 2026 at 12:00 PM CT, currently marked as tentative.
Eligibility Criteria
- Applications must be investigator-initiated.
- Applicants may represent an academic, nonprofit, for-profit, research, or medical institution.
- Institutions and trials may be based internationally.
- Gateway primarily funds Phase I and Phase II clinical trials.
- Research may address any cancer type, including rare cancers.
- Projects should be treatment-focused and strongly aligned with Gateway’s patient-centered research mission.
Funding Details
- Award range: Approximately $200,000–$1.5 million.
- Maximum funding: $1.5 million.
- Average Gateway award: approximately $500,000.
- Typical project duration: 2–5 years.
Deadline
- Applications are accepted year-round.
- Gateway aggregates applications for review twice per year.
- Next LOI deadline: November 6, 2026 at 12:00 PM CT — tentative.
Further Information
- Initial IRB/IEC and IND approval does not need to be in place at LOI submission, but must be obtained within the required post-award timeframe.
- Official program page: View Gateway grant programs
- Research criteria and eligibility: View Gateway Research FAQs
- Application portal: Apply through Gateway